NCT03012646

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

A Prospective, Multicenter, Single-arm Study to Evaluate the Safety and Tolerability of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: United Therapeutics · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

• Pulmonary Hypertension
• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Inhaled Treprostinil	Inhaled treprostinil (6 mcg/breath) administered four times daily

Timeline

• Start date: 2017-04-01
• Primary completion: 2019-04-01
• Completion: 2019-04-01
• First posted: 2017-01-06
• Last updated: 2017-04-11

Regulatory

• FDA-regulated drug study